BCM
ZNTL icon

Bridgeway Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bridgeway Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$181K Hold
77,300
– – ﹤0.01% 1052
2025
Q4 		$104K Hold
77,300
– – ﹤0.01% 1119
2025
Q3 		$117K Hold
77,300
– – ﹤0.01% 1091
2025
Q2 		$89.7K Sell
77,300
-75,000
-49% -$98.9K ﹤0.01% 1089
2025
Q1 		$242K Sell
152,300
-22,700
-13% -$49K 0.01% 879
2024
Q4 		$530K Buy
+175,000
New +$574K 0.01% 802

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Bridgeway Capital Management's ZNTL Position: Q1 2026 in Review

Bridgeway Capital Management held its Zentalis Pharmaceuticals (ZNTL) position steady in Q1 2026 at 77,300 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #1052.

Bridgeway Capital Management first reported a position in ZNTL in Q4 2024 and has held it in 6 quarters since. The position peaked at $530K in Q4 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Bridgeway Capital Management held 77,300 shares of Zentalis Pharmaceuticals worth $181K as of Q1 2026.
  • Bridgeway Capital Management left its Zentalis Pharmaceuticals share count unchanged in Q1 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1052 holding.
  • Bridgeway Capital Management first reported a position in Zentalis Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Bridgeway Capital Management's Zentalis Pharmaceuticals position peaked at $530K in Q4 2024.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.